The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Storosum, J. G.
* Articles by van den Brink, W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Storosum, J. G.
* Articles by van den Brink, W.
Related Collections
* Other Ethics Issues
* Bipolar Disorder
* Suicide
Am J Psychiatry 162:799-802, April 2005
© 2005 American Psychiatric Association


Brief Report

Suicide Risk in Placebo-Controlled Trials of Treatment for Acute Manic Episode and Prevention of Manic-Depressive Episode

Jitschak G. Storosum, M.D., Ph.D., Tamar Wohlfarth, Ph.D., Christine C. Gispen-de Wied, M.D., Ph.D., Don H. Linszen, M.D., Ph.D., Berthold P.R. Gersons, M.D., Ph.D., Barbara J. van Zwieten, Ph.D., and Wim van den Brink, M.D., Ph.D.

OBJECTIVE: The authors’ goal was to investigate whether there is a greater suicide risk in the placebo arms of placebo-controlled studies of active medication for the treatment of acute manic episode and the prevention of manic/depressive episode. If so, this would be a strong ethical argument against the conduct of such studies. METHOD: All placebo-controlled, double-blind, randomized trials of medication for the treatment of acute manic episode and the prevention of manic/depressive episode that were part of a registration dossier submitted to the regulatory authority of the Netherlands, the Medicines Evaluation Board, between 1997 and 2003, were reviewed for occurrence of suicide and attempted suicide. RESULTS: In 11 placebo-controlled studies of the treatment of acute manic episode, including 1,506 patients (117 person-years) in the combined active compound group and 1,005 patients (71 person-years) in the combined placebo group, no suicides and no suicide attempts occurred. In four placebo-controlled studies of the prevention of manic/depressive episode, including 943 patients (406 person-years) in the combined active compound group and 418 patients (136 person-years) in the combined placebo group, two suicides (493/100,000 person-years of exposure) and eight suicide attempts (1,969/100,000 person-years of exposure) occurred in the combined active compound group, but no suicides and two suicide attempts (1,467/100,000 person-years of exposure) occurred in the combined placebo group. CONCLUSIONS: Concern about greater risk of suicide or attempted suicide in the placebo group should not be an argument against the conduct of placebo-controlled trials for these indications, provided that appropriate precautions are taken.




This article has been cited by other articles:


Home page
Am. J. PsychiatryHome page
R. D. GOLDNEY
Suicide Risk in Placebo-Controlled Trials of Bipolar Disorder
Am J Psychiatry, February 1, 2006; 163(2): 329 - 329.
[Full Text] [PDF]


Home page
Psychiatr. NewsHome page
M. Moran
No Rise in Suicides Found In Mania-Treatment Trials
Psychiatr News, May 20, 2005; 40(10): 51 - 51.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org